Abstract
The lead optimization of a series of N-substituted benzimidazole CXCR4 antagonists is described. Side chain modifications and stereochemical optimization led to substantial improvements in potency and protein shift to afford compounds with low nanomolar anti-HIV activity.
2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Anti-HIV Agents / chemistry*
-
Anti-HIV Agents / pharmacology*
-
Benzimidazoles / chemistry*
-
Benzimidazoles / pharmacology*
-
Cell Line
-
HIV Infections / drug therapy*
-
HIV-1 / drug effects*
-
Humans
-
Inhibitory Concentration 50
-
Receptors, CXCR4 / antagonists & inhibitors*
-
Receptors, CXCR4 / metabolism
Substances
-
Anti-HIV Agents
-
Benzimidazoles
-
Receptors, CXCR4